Untitled attachment

Notices where this attachment appears

1. Embed this notice
   HebrideanHecate (hebrideanhecate@spinster.xyz)'s status on Tuesday, 06-Jan-2026 03:55:20 JST HebrideanHecate

   https://www.transgendertrend.com/pathways-puberty-blocker-trial-cass-review/

   Patient safety and evidence-based care must be the priority for the NHS regarding medical interventions for children. The PATHWAYS puberty blocker trial is not a prioritisation of patient safety as it lacks an evidence base.

   Developing the evidence base should be the priority before a trial on a new cohort of children is even considered.

   The Cass Review should not be used as justification to run a trial of puberty blockers. This was only one Recommendation of 32 Recommendations in total. To go forward with this one Recommendation while ignoring others that are crucial to put in place first, is using the Cass Review to implement an agenda, not following it to ensure patient safety and evidence-based treatment.

   Data obtained by the Telegraph showed that 3,490 women were referred for ‘masculinising chest surgery’ on the NHS between 2021 and 2023, and that the number has risen slightly each year, from 1,089 in 2021 to 1,164 in 2022 and 1,237 in 2023.

   Over three years, more than 780 women were referred for ‘masculinising genital gender reassignment surgery’, an experimental surgery with poor results and commonly-experienced complications.

   The Telegraph report tells us ‘As many as 80 per cent of people using those services are females between the ages of 17 and 25’, which aligns with the figure reported by the Cass Review that referrals were ‘70-80 per cent birth-registered females under the age of 25’.